Decoy Therapeutics Inc.
Decoy Therapeutics Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture pe… Read more
Market Cap & Net Worth: Decoy Therapeutics Inc. (DCOY)
Decoy Therapeutics Inc. (NASDAQ:DCOY) has a market capitalization of $80.39K ($80.39K) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #41577 globally and #13518 in its home market, demonstrating a -6.48% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Decoy Therapeutics Inc.'s stock price $8.08 by its total outstanding shares 9949 (9.95K).
Decoy Therapeutics Inc. Market Cap History: 2026 to 2026
Decoy Therapeutics Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $80.39K to $80.39K (0.00% CAGR).
Decoy Therapeutics Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Decoy Therapeutics Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of DCOY by Market Capitalization
Companies near Decoy Therapeutics Inc. in the global market cap rankings as of March 19, 2026.
Key companies related to Decoy Therapeutics Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Decoy Therapeutics Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, Decoy Therapeutics Inc.'s market cap moved from $80.39K to $ 80.39K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $80.39K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Decoy Therapeutics Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $80.39K USD |
| MoneyControl | $80.39K USD |
| MarketWatch | $80.39K USD |
| marketcap.company | $80.39K USD |
| Reuters | $80.39K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.